SEC Form 4 · accession 0000874015-15-000036
IONIS PHARMACEUTICALS INC · IONS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph Klein III
Director
Period of report
Mar 5, 2015
Accepted (ET)
Mar 9, 2015 · 7:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874015
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 5, 2015 | M | 3,750 | $9.22 | A | 4,845 | D | |
| Common StockF1 | Mar 5, 2015 | M | 3,750 | $9.30 | A | 8,595 | D | |
| Common StockF1 | Mar 5, 2015 | M | 2,500 | $12.94 | A | 11,095 | D | |
| Common StockF4,F2 | Mar 5, 2015 | S | 7,000 | $70.9545 | D | 4,095 | D | |
| Common Stock | holding | — | — | — | 100 | I | By son |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Director Stock Option (right to buy) | $9.22 | Mar 5, 2015 | M | 3,750 | D | Jul 1, 2014 | Jun 30, 2020 | Common Stock | 3,750 | 0 | D |
| Director Stock Option (right to buy)F3 | $9.30 | Mar 5, 2015 | M | 3,750 | D | Jul 1, 2012 | Jun 30, 2021 | Common Stock | 3,750 | 3,750 | D |
| Director Stock Option (right to buy)F5 | $12.94 | Mar 5, 2015 | M | 2,500 | D | Jul 2, 2013 | Jul 1, 2022 | Common Stock | 2,500 | 5,937 | D |
Explanation of responses
- F1Acquired as a result of exercising a stock option.
- F2The sale was a result of shares owned. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.8500 to $71.0300, inclusive. The reporting person undertakes to provide to Isis Pharmaceuticals, Inc., any security holder of Isis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
- F3Grant of 7/1/2011 to reporting person of stock options under the Isis Pharmacueticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on 7/1/2012. The option shal be fully vested and exercisable on 7/1/2015. Following the reported option exercise, the option was exercisable as to 0 shares on 3/5/2015.
- F4The sale was made pursuant to shares owned.
- F5Grant of 7/2/2012 to reporting person of stock options under the Isis Pharmacueticals, Inc. Amended & Restated 2002 Non-Employee Directors' Stock Option Plan. The option vests and becomes exercisable in four equal annual installments, the first installment vesting on 7/2/2013. The option shal be fully vested and exercisable on 7/2/2016. Following the reported option exercise, the option was exercisable as to 313 shares on 3/5/2015.